Amgen Reflects Relief From Bundling Rules, Optimistism About Prolia
This article was originally published in The Pink Sheet Daily
Executive Summary
Oral drugs are ruled exempt until 2014 from a new dialysis payment plan, and hopes are high for an osteoporosis drug to become a cancer blockbuster.
You may also be interested in...
FDA Approves Amgen's Denosumab For First Oncology Indication
Known as Prolia for osteoporosis, the drug will be called Xgeva for skeletal-related events related to metastasized solid-tumor cancers.
FDA Approves Amgen's Denosumab For First Oncology Indication
Known as Prolia for osteoporosis, the drug will be called Xgeva for skeletal-related events related to metastasized solid-tumor cancers.
CMS Delays Inclusion Of Oral-Only ESRD Drugs In Final Bundled Payment Rule For Medicare
Inclusion of oral-only drugs in bundled payment will be delayed until 2014, allowing CMS to address pricing and data issues, but the decision does not alter the agency's interpretation that oral-only drugs should be a part of the bundle.